Cargando…
Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems...
Autores principales: | Baindara, P., Chakraborty, R., Holliday, Z.M., Mandal, S.M., Schrum, A.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785423/ https://www.ncbi.nlm.nih.gov/pubmed/33425362 http://dx.doi.org/10.1016/j.nmni.2021.100837 |
Ejemplares similares
-
Molecular pathogenesis of secondary bacterial infection associated to viral infections including SARS-CoV-2
por: Manna, Sounik, et al.
Publicado: (2020) -
Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
por: Earhart, A.P., et al.
Publicado: (2020) -
Conservation and Enhanced Binding of SARS-CoV-2 Omicron Spike Protein to Coreceptor Neuropilin-1 Predicted by Docking Analysis
por: Baindara, Piyush, et al.
Publicado: (2022) -
Preventing Respiratory Viral Diseases with Antimicrobial Peptide Master Regulators in the Lung Airway Habitat
por: Baindara, Piyush, et al.
Publicado: (2023) -
Coronavirus disease 2019 and the gut–lung axis
por: Zhou, Dan, et al.
Publicado: (2021)